Aristotle University Of Thessaloniki (AUTH)
In vitro & in vivo μελέτη της επίδρασης του αναστολέα της SRC τυροσινικής κινάσης Dasatinib και του χημειοθεραπευτικού ντοσεταξέλη σε πειραματικά μοντέλα Triple-negative καρκίνου του μαστού
Abstract
dc:descriptionBACKROUND: The term “triple-negative breast cancer” (TNBC) is used to identifythe approximately 15% of breast cancers that lack expression of estrogen receptor (ER)and progesterone receptor (PR) and do not show amplification of the human epidermalgrowth factor receptor 2 (HER2) gene. TNBCs are a heterogeneous group of tumorswith one common feature: a distinctly aggressive nature with higher rates of relapseand shorter overall survival in the metastatic setting compared to other subtypes ofbreast cancer. To date, not a single targeted therapy has been approved for the treatmentof TNBC, and cytotoxic chemotherapy remains the standard treatment. OBJECTIVE: The experimental study of the effects of the chemotherapeutic docetaxeland the bcr/abl kinase inhibitor dasatinib on triple- negative breast cancer cell lines (invitro) and on TNBC tumor xenograft mouse models (in vivo). MATERIALS AND METHODS: TNBC cell lines were cultivated and treated withvarious concentrations of docetaxel and dasatinib (5 nM to 100nM). Cell death andapoptosis were studied by flow cytometry. TNBC cell lines were then injected inBALB/c athymic nude mice to express the tumor in vivo. Four groups of mice werecreated (group A: Control, group B: DOC, group C: DAS, group D: DOC + DAS) andtreated respectively with the drugs and their combination. Tumors were obtained,maintained in formaldehyde solution of 10%, embedded in paraffin and sent for furtherhistological evaluation (hematoxylin- eosin staining and immune-histochemicalanalysis) to assess the tumor growth inhibition. RESULTS: The cytotoxic effects of docetaxel seem to be statistically important, withlittle effect on apoptosis. The effect of dasatinib in vitro and vivo is statisticallyimportant, in terms of apoptosis and tumor reduction, with little adverse effects. CONCLUSION: TNBC is a difficult to treat oncologic condition, even in theexperimental setting. Promising results concerning the addition of targeted therapies(dasatinib) to the conventional cytotoxic ones (docetaxel) have been shown, awaitingfurther evaluation.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Passos, Ioannis
- Πάσσος, Ιωάννης
Subjects
dc:subject × 18- Τριπλά- Αρνητικός Καρκίνος Μαστού
- Ντοσεταξέλη
- Δασατινίμπη
- Αναστολείς τυροσινικής κινάσης
- Χημειοθεραπεία
- Στοχευμένη θεραπεία
- Triple- negative breast cancer
- Docetaxel
- Dasatinib
- Tyrosine kinase inhibitors
- Chemotherapy
- Targeted therapies
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Φαρμακολογία και Φαρμακευτική
- Basic Medicine
- Medical and Health Sciences
- Pharmacology and Pharmacy
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/52929